The company behind the test said there were positive signs that some of the most aggressive cancers could be prevented.
Trending
- Evorpacept plus trastuzumab, ramucirumab and paclitaxel in HER2-positive gastric cancer: a randomized phase 2 trial
- Daratumumab Combo Yields Responses in Cardiac-Involved AL Amyloidosis Trials
- Understanding cancer promotion and preventing pathologies of ageing
- Cevostamab Combo Shows Durable Responses in R/R Multiple Myeloma
- MELT-MM Regimen Yields Responses in Relapsed/Refractory Multiple Myeloma
- Belzutifan Combo Receives FDA Approval in Advanced Clear Cell RCC
- SOHO-02 Trial Will Confirm Sevabertinib’s Frontline NSCLC Benefit
- Synonymous codon usage shapes ERα function through specialized translational programs during breast cancer progression
Friday, September 25
